Novavax, Inc.  

(Public, NASDAQ:NVAX)   Watch this stock  
Find more results for NVAX
8.87
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 3.92 - 9.95
Open     -
Vol / Avg. 0.00/3.14M
Mkt cap 2.37B
P/E     -
Div/yield     -
EPS -0.40
Shares 268.03M
Beta 1.28
Inst. own 66%
Aug 4, 2015
Q2 2015 Novavax Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 7, 2015
Q1 2015 Novavax Inc Earnings Call
May 7, 2015
Q1 2015 Novavax Inc Earnings Release
Apr 15, 2015
Novavax Inc at Needham Healthcare Conference
Feb 26, 2015
Q4 2014 Novavax Inc Earnings Call
Feb 26, 2015
Q4 2014 Novavax Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -246.73% -270.55%
Operating margin -246.16% -272.97%
EBITD margin - -255.03%
Return on average assets -27.35% -32.46%
Return on average equity -31.06% -38.33%
Employees 308 -
CDP Score - -

Address

20 Firstfield Rd
GAITHERSBURG, MD 20878-1760
United States - Map
+1-240-2682000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company focusing on developing recombinant vaccines. The Company’s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company's vaccine candidates are genetically engineered three-dimensional nanostructures, which incorporate immunologically important recombinant proteins. The Company's product pipeline focuses on a variety of infectious diseases and the Company's vaccine candidates have completed clinical trials that target pandemic influenza (H5N1), seasonal influenza and respiratory syncytial virus (RSV). The Company’s joint venture, Cadila Pharmaceuticals Limited (CPL) Biologics Private Limited, develops a rabies vaccine candidate that is genetically engineered by Novavax. CPL Biologics Private Limited completed initial pre-clinical immunogenicity studies on this new vaccine candidate and is progressing with pre-clinical toxicology studies.

Officers and directors

James F. Young Ph.D. Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Stanley C. Erck President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Barclay A. Phillips Chief Financial Officer, Senior Vice President, Treasurer
Age: 52
Bio & Compensation  - Reuters
Gregory M. Glenn M.D. Senior Vice President - Research & Development
Age: 61
Bio & Compensation  - Reuters
Timothy J. Hahn Ph.D. Senior Vice President - Manufacturing and Process Development
Age: 51
Bio & Compensation  - Reuters
John J. Trizzino Senior Vice President - Commercial Operations
Age: 55
Bio & Compensation  - Reuters
Russell P. Wilson J.D. Senior Vice President - Business Development
Age: 55
Bio & Compensation  - Reuters
D. Nigel Thomas Vice President - Clinical Operations
Bio & Compensation  - Reuters
Rajiv I. Modi Ph.D. Director
Age: 54
Bio & Compensation  - Reuters
Richard H. Douglas Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters